(February 1, 2017, 8:13 AM EST) -- BOSTON — Eleven diabetics on Jan. 30 filed a class action complaint alleging that Sanofi U.S., Novo Nordisk Inc. and Eli Lilly and Co. are raising their prices for insulin out of reach for some diabetics to create a “spread” between the drugs’ “list price” and its wholesale price to stay on the formularies of pharmacy benefit managers (PBMs) (Donald Chaires, et al. v. Sanofi U.S., et al., No. 17-10158, D. Mass.)....